BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Syndeio Biosciences readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Syndeio Biosciences's drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06547489-869@assetmemo.bio
DTSTAMP:20261121T010438Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Zelquistinel: Phase 2 readout est. (NCT06547489)
DESCRIPTION:Zelquistinel\, phase 2\, Major Depressive Disorder.\nStudy: Zel
 quistinel or Placebo for the Reduction of Symptoms of Major Depressive Dis
 order\nEstimated primary completion: September 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/zelquistinel#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06547489
URL:https://assetmemo.bio/drug/zelquistinel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07115329-869@assetmemo.bio
DTSTAMP:20261121T010438Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Zelquistinel: Phase 2 readout est. (NCT07115329)
DESCRIPTION:Zelquistinel\, phase 2\, Major Depressive Disorder.\nStudy: A P
 hase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of M
 ajor Depressive Disorder\nEstimated primary completion: 30 March 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/zelquistinel#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07115329
URL:https://assetmemo.bio/drug/zelquistinel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
